Key facts
- Bullseye Bio’s last known valuation is $9.5M (Apr 2025).
- It has raised $2.5M; the latest was Seed Round ($2.5M) in Apr 2025.
- Notable investors include US National Science Foundation, Harvard Innovation Launch Lab, ZAKA VC, Mission BioCapital, Illumina Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Bullseye Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Bullseye Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bullseye Bio
Operator of a therapeutics discovery intended to generate scalable data for machine learning, unlocking the therapeutic potential of intracellular protein-protein interactions. The company offers medicines regarding cardiometabolic, inflammation, and oncology, enabling patients to get life-saving treatments for high-need conditions.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2023
- Employees
- 4
- Website
- bullseyebiosciences.com/
- Ownership
- Privately Held (backing)
Bullseye Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bullseye Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bullseye Bio in its N-PORT filings yet. We sweep new filings monthly.